SCHEMBL14820113

SCHEMBL14820113

CC(C1CCN(C)CC1)N1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.37
L3MBTL3 Q96JM7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KCNH2 Q12809 1/20 0.32
NCF1 P14598 1/20 0.30
IKZF2 Q9UKS7 1/20 0.30
DRD2 P14416 1/20 0.30
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30
SIGMAR1 Q99720 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26241782 1.00 POLB (0.46) POLBALDH1A1KDM4EL3MBTL3L3MBTL1
SCHEMBL18081296 1.00 POLB (0.46) POLBALDH1A1KDM4EL3MBTL3L3MBTL1
SCHEMBL20008983 0.84 POLB (0.46) POLBALDH1A1KDM4ELMNAMAPT
SCHEMBL20009031 0.84 POLB (0.46) POLBALDH1A1KDM4ELMNAMAPT
SCHEMBL20009046 0.84 POLB (0.46) POLBALDH1A1KDM4ELMNAMAPT
SCHEMBL11602937 0.83 POLB (0.44) POLBALDH1A1KDM4ELMNAMAPT
SCHEMBL22565540 0.83 L3MBTL3 (0.47) POLBKDM4EL3MBTL3L3MBTL1KCNH2
SCHEMBL26517435 0.83 L3MBTL3 (0.47) POLBKDM4EL3MBTL3L3MBTL1KCNH2
SCHEMBL26517434 0.83 L3MBTL3 (0.47) POLBKDM4EL3MBTL3L3MBTL1KCNH2
SCHEMBL12124972 0.82 POLB (0.43) POLBALDH1A1KDM4EL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 EP disclosed
US-20170037059-A1 GYRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-02-09 US disclosed
US-9481675-B2 Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-01 US disclosed
US-20130079323-A1 GYRASE INHIBITORS TRIUS THERAPEUTICS, INC. (US) 2013-03-28 US disclosed
US-7192949-B2 Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors MERCK & CO., INC. (US) 2007-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037059-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B POLB 194/4885ALDH1A1 2837/4885KDM4E 1199/4885
US-20130079323-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B POLB 194/4885ALDH1A1 2837/4885KDM4E 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.